期刊文献+

依达拉奉对糖尿病周围神经病变氧化应激和神经传导速度的影响 被引量:3

下载PDF
导出
摘要 目的 观察依达拉奉对糖尿病周围神经病变(DPN)患者氧化应激状态和神经传导速度的影响,评价疗效.方法 40例DPN患者予依达拉奉60mg/d,静脉滴注2周,检测治疗前后氧化和抗氧化系统指标和神经传导速度,并进行总体症状评分(TSS).结果 治疗后DPN患者血清一氧化氮(NO)、丙二醛(MDA)含量明显降低,超氧化物歧化酶(SOD)活力明显提高,运动神经传导速度(MCV)、感觉神经传导速度(SCV)显著增快,TSS评分明显下降,差异均有统计学意义(P<0.01).结论 依达拉奉可抑制DPN患者氧化应激,提高神经传导速度,改善临床症状. Objective To observe the edaravone on oxidative stress and nerve conduction velocity in patients with diabetic peripheral neuropathie$. Methods 40 cases of patients with diabetic peripheral neuropathies were treated with edaravone 60rag daily intravenously for two weeks. Oxidative stress, nerve conduction velocity and total symptoms score were measured before and after the treatment. Results After edaravone treatment, there were significant decreac in NO and MDA level and increase in SOD activity ( P 〈 0. 01 ). MCV and SCV were significant improved(P 〈0. 01 ).There was significant decreae in TSS (P 〈0. 01 ). Conclusions edaravone can inhibit the oxidative stress and improve MCV and SCV in patients with diabetic peripheral neuropathies, improve the clinical symptoms.
出处 《浙江临床医学》 2012年第1期11-13,共3页 Zhejiang Clinical Medical Journal
基金 徐州市科技计划项目(XM09B080)
关键词 依达拉奉 糖尿病周围神经病变 氧化应激 神经传导速度 Edaravone Diabetic peripheral neuropathy Oxidative stress Nerve conduction velocity
  • 相关文献

参考文献16

二级参考文献89

共引文献101

同被引文献33

  • 1王驰仲,赵永波.糖尿病性神经病变[J].神经疾病与精神卫生,2006,6(4):296-297. 被引量:14
  • 2Kawagashira Y, Watanabe H, Morozumi S, et al. Differential response to intravenous immunoglobulin (IVIg) therapy among muhifocal and poly- neuropathy types of painful diabetic neuropathy [ J ]. Journal of clinical ,2010,17(8) :1003 - 1008.
  • 3钱荣立;项坤山.中国糖尿病防治指南[M]北京:北京大学出版社,2004138-139.
  • 4Brownlee M. The pathhobiology of diabetic complications:a unifying methanistm[J].Diabetics,2005,(06):1615-1625.
  • 5Ohmura C,Watada H,Azuma K. Aldose reductase inhibitor,epalrestat,reduces lipid hydroperoxides in type 2 diabetes[J].Endocrine Journal,2009,(01):149-156.
  • 6Das Evcimen N,King GL. The role of protein kinase C activiation and the vascular complications of diabetes[J].Pharmacological Research,2007,(06):498-510.doi:10.1016/j.phrs.2007.04.016.
  • 7Hotta N,Akanuma Y,Kawamori R. Long-term clinical effects of epalrestat,an aldose reductase inhibitor,on diabetic peripheral neuropathy:the 3-year,multicenter,comparative Aldose Reductase Inhibitor-Diabetes Complications Trial[J].Diabetes Care,2006,(07):1538-1544.doi:10.2337/dc05-2370.
  • 8Lee J,Lee HI,Seo KI,Cho HW,et al.Effects of ursolic acid on glucose\smetabolism,the polyol pathway and dyslipidemia in non-obese type 2diabetic mice[J].Indian J Exp Biol,2014,52(7):683-691.
  • 9Srivastava S,Ramana KV,Tammali R,et al.Contribution of aldose reductase to diabetic hyperoliferation of vascular smooth musceI cells[J].Diabetes,2006,55(4):901-10.
  • 10Rahbar S,Natarajan R,Yerneni K,et al.Evidence that pioglitazone,metformin and pentoxifylline are inhibitors of glycation[J].Clin Chim\sActa,2000,301(1-2):65-77.

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部